Sandu Pharmaceuticals Limited — Quarter ended 31st March 2026 (Standalone)
Annexure II — Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:
| SrNo | Particulars | Details |
|---|---|---|
| 1. | Reason for change viz. appointment, reappointment, otherwise completion of their terms | Reappointment |
| 2. | Date of appointment/cessation and terms of appointment | Date of Reappointment: 05.05.2026; Term: Financial Year 2026-27 |
| 3. | Brief Profile (in case of appointment) | M/s Shekhar Joshi & Co is a firm of Cost Accountants practicing as Cost Accountant (Registration No. 100448). CMA Shekhar Joshi is M.Com, LL.B, FCMA, M.B.A. with 35 plus years of experience. He is Visiting Faculty at the ICFAI Business School, Sterling Institute of Management, The Atharva Institute of Management Studies, Finplan Institute and Institute of Cost Accountants of India. Areas of Specialization: Cost Audit Management, Consultancy, Statutory Compliances, Business Valuation for Banking and Take Overs, Assisting Mergers and Acquisition Due Diligences, Project Appraisal and Evaluations, Internal and MIS systems, Stock Audits, Product Costing, Market Profitability Analysis, Cost Audit and Cost Compliance Implementation of Costing Systems, Due Diligences, Feasibility study of Mergers, Corporate Valuation, MIS Implementation, Costing MIS and Routine Assistance, Budgets and Follow ups. |
| 4. | Disclosure of relationships between directors (in case of appointment) | M/s Shekhar Joshi & Co, Cost Auditors is not related to any of the Directors or Key Managerial Personnel or Promoters and Promoter group of the Company. |
Annexure III — Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:
| Sr No | Details of events that need to be provided | Information of such event(s) |
|---|---|---|
| Reappointment | ||
| 1. M/S Akhil Pai & Co | ||
| 2. M/S Uday & Uday Associates | ||
| 1 | Reason for change viz. appointment, resignation, removal, death or otherwise completion of their terms | Considering the term of expiry of internal auditor for Goa Plant operations, CA Akhil Pai & Co is reappointed for further period of 01 year that is for the FY 2026-27. Considering the term of expiry of internal auditor for Mumbai, CA Akhil Pai & Co is reappointed for further period of 01 year that is for the FY 2026-27 |
| 2 | Date of appointment/cessation and terms of appointment | 05.05.2026; Term: for the FY 2026-27 |
| 3 | Brief Profile (in case of appointment) | He is Practising Chartered Account. He has conducted Tax Audits of Proprietorship Concerns, Firms and Companies, and also looks into other Companies law matters, Income Tax related & GST matters. |
| 4 | Disclosure of relationships between directors (in case of appointment) | Akhil Pai & Co is not related to any of the Directors or Key Managerial Personnel or Promoters and Promoter group of the Company. |
Statement of Profit and Loss for the Period ended 31st March, 2026 (Rs in lakhs):
| Particulars | 3 Months ended 31st March 2026 Audited |
Preceeding 3 Months Ended 31st December 2025 Unaudited |
Corresponding 3 Months ended 31st March 2025 Audited |
Year ended 31st March 2026 Audited |
Year ended 31st March 2025 Audited |
|---|---|---|---|---|---|
| INCOME | |||||
| Revenue From Operations | 1685.34 | 1876.09 | 1406.92 | 6993.45 | 6719.24 |
| Other Income | 36.51 | 1.37 | 6.94 | 44.44 | 16.75 |
| Total Income | 1721.85 | 1877.46 | 1413.85 | 7037.89 | 6735.99 |
| EXPENSES | |||||
| Cost of materials consumed | 383.94 | 281.31 | 301.49 | 1101.18 | 1011.98 |
| Purchases of Stock-in-Trade | 351.54 | 349.94 | 728.92 | 1648.07 | 2318.45 |
| Changes in inventories of finished goods, Stock-in-Trade and work-in-progress | -83.01 | 157.47 | -452.56 | 407.95 | -120.24 |
| Employee benefits expense | 274.28 | 264.65 | 282.74 | 1069.08 | 1092.03 |
| Finance costs | 2.56 | 3.35 | 2.63 | 11.21 | 10.33 |
| Depreciation and amortization expense | 16.43 | 16.58 | 14.81 | 67.70 | 67.06 |
| Other expenses | 701.34 | 718.66 | 501.57 | 2467.16 | 2340.80 |
| Total expenses | 1647.14 | 1791.96 | 1379.61 | 6772.35 | 6520.41 |
| Profit/(loss) before exceptional items and tax | 74.71 | 85.50 | 34.24 | 265.54 | 215.58 |
| Exceptional Items / Prior Period Adjustment | .00 | .00 | .00 | .00 | .00 |
| PROFT/(LOSS) BEFORE TAX | 74.71 | 85.50 | 34.24 | 265.54 | 215.58 |
| Tax expense: | |||||
| Current tax | -42.13 | 4.89 | 7.41 | -56.64 | -58.86 |
| Deferred tax | -16.36 | 7.12 | (5.81) | -10.41 | -1.83 |
| Short / (Excess) Tax Provision | -11.89 | .00 | .00 | -11.89 | .00 |
| PROFIT (LOSS) FOR THE PERIOD | 4.34 | 97.51 | 32.64 | 176.61 | 154.89 |
| OTHER COMPREHENSIVE INCOME | |||||
| Items that will not be reclassified to profit or loss in Subsequent Periods: | |||||
| Remeasurement gains/(losses) on post employment defined benefit plans | 8.11 | .00 | (12.66) | 8.11 | -12.66 |
| Fair value changes of investments | 74.61 | 19.70 | 21.35 | 74.61 | 82.95 |
| Income tax relating to items that will not be reclassified to profit or loss | -16.38 | -2.74 | 1.15 | -16.38 | -5.71 |
| Total other comprehensive income for the period (net of tax) | 66.35 | 16.96 | 9.84 | 66.35 | 64.58 |
| Total comprehensive income for the period (net of tax) | 70.68 | 114.47 | 42.48 | 242.95 | 219.47 |
| Paid Up Equity Capital | 966.10 | 966.10 | 966.10 | 966.10 | 966.10 |
| (Face Value of Rs. 10/- Per share) | |||||
| EARNINGS PER EQUITY SHARE | |||||
| Basic | 0.04 | 1.01 | 0.34 | 1.83 | 1.60 |
| Diluted | 0.04 | 1.01 | 0.34 | 1.83 | 1.60 |
Balance Sheet as at 31st March, 2026 (Rs in lakhs):
| PARTICULARS | As at 31st March, 2026 | As at 31st March, 2025 |
|---|---|---|
| Amount (₹) | Amount (₹) | |
| ASSETS | ||
| Non-current assets | ||
| Property, Plant and Equipment | 868.47 | 846.56 |
| Right of use assets | 942.13 | 965.62 |
| Capital Work in Progress | 6.41 | – |
| Other Intangible Assets | 1.86 | 2.39 |
| Financial Assets | ||
| Investments | 1229.80 | 1122.42 |
| Other Financial Asset | 3.08 | 5.00 |
| Other Non-Current Assets | 3.24 | – |
| Total Non-current Assets | 3054.99 | 2941.98 |
| Current assets | ||
| Inventories | 1047.13 | 1414.86 |
| Financial Assets | ||
| Trade receivables | 541.09 | 475.73 |
| Cash and cash equivalents | 590.77 | 130.39 |
| Bank balances other than 9 (a) above | 94.82 | 134.91 |
| Other current assets | 258.11 | 473.99 |
| Total Current Assets | 2531.94 | 2629.88 |
| TOTAL ASSETS | 5586.93 | 5571.87 |
| PARTICULARS | As at 31st March, 2026 | As at 31st March, 2025 |
|---|---|---|
| Amount (₹) | Amount (₹) | |
| EQUITY AND LIABILITIES | ||
| Equity | ||
| Equity Share capital | 966.10 | 966.10 |
| Other Equity | 3401.23 | 3235.62 |
| Total Equity | 4367.33 | 4201.72 |
| Non-current liabilities | ||
| Financial Liabilities | ||
| Finance Lease obligations | 30.95 | 41.93 |
| Deferred tax liabilities (Net) | 146.44 | 119.64 |
| Total Non-current Liabilities | 177.39 | 161.57 |
| Current liabilities | ||
| Financial Liabilities | ||
| Finance Lease obligations | 10.98 | 5.82 |
| Trade payables Due to: | ||
| – Micro and Small Enterprises | 61.72 | 32.72 |
| – Other than Micro and Small Enterprises | 385.03 | 416.00 |
| Other Financial Liabilities | 31.27 | 25.00 |
| Other current liabilities | 206.59 | 190.67 |
| Provisions | 346.63 | 538.35 |
| Total Current Liabilities | 1042.21 | 1208.58 |
| TOTAL EQUITY AND LIABILITIES | 5586.93 | 5571.87 |
Statement of Cash Flow for the year ended 31st Mar, 2026 (Rs in lakhs):
| Particulars | Year ended 31st Mar, 2026 | Year ended 31st March, 2025 |
|---|---|---|
| A. Cash flow from operating activities | ||
| Net Profit / (Loss) before extraordinary items and tax | 265.54 | 215.58 |
| Adjustments for: | ||
| Depreciation and amortisation expenses | 67.70 | 67.06 |
| Finance costs | 11.21 | 10.33 |
| Interest income | -5.89 | (11.05) |
| Other Income | .00 | .67 |
| Loss on Sale of Investment in Subsidary Sandu Phytoceticals P Ltd | .00 | 0.33 |
| Allowance for doubtful debts / expected credit losses – trade receivable | 48.60 | 16.11 |
| Equity Instruments through Other Comprehensive Income | .00 | .00 |
| Re-measurement gains/losses on employee defined benefit plans | 8.11 | (12.66) |
| Operating profit / (loss) before changes in operating assets & liabilities | 395.26 | 285.70 |
| Changes in operating assets | ||
| (Increase) / decrease in inventories | 367.73 | (189.80) |
| (Increase) / decrease in Trade receivables | -113.96 | (5.02) |
| (Increase) / decrease in other operating assets | 25.71 | (17.81) |
| Changes in operating liabilities | ||
| (Increase) / decrease in trade payables | -2.09 | 29.34 |
| (Increase) / decrease in other operating liabilities | 13.84 | 50.55 |
| Cash Generated from operation | 686.56 | 153.00 |
| Income Tax Paid | -74.98 | (58.32) |
| Net Cash flow from Operating activities | 611.58 | 95.04 |
| B. Cash flow from investing activities | ||
| Purchases of Property, Plant and Equipment | -72.00 | (93.80) |
| Proceeds from Maturity of Fixed Deposits placed with Banks | 70.00 | 191.90 |
| Fixed deposits placed with banks | -28.00 | (130.00) |
| Interest received | 5.89 | 11.05 |
| Other Income | .00 | 0.67 |
| Proceed from Sale of Investment in Subsidary Sandu Phytoceticals P Ltd | .00 | .00 |
| Proceeds from Sales of Mutual Funds /Shares | 74.63 | 152.23 |
| Purchases of Mutual fund / Shares designated at FVTOCI | -107.38 | (150.00) |
| Net cash flow from / (used in) investing activities (B) | -56.86 | (17.96) |
| C. Cash flow from financing activities | ||
| Finance lease obligations | -5.82 | 41.42 |
| Finance cost | -11.21 | (10.33) |
| Dividends Paid | -77.29 | (77.29) |
| Net cash flow from / (used in) financing activities (C) | -94.32 | (46.20) |
| Net increase / (decrease) in Cash and cash equivalents (A+B+C) | 460.38 | 30.84 |
| Cash and cash equivalents at the beginning of the year | 130.39 | 99.55 |
| Cash and cash equivalents at the end of the year | 590.77 | 130.39 |
Reconciliation of cash and cash equivalents with the balance sheet (Rs in lakhs):
| Particulars | 31st March, 2026 | 31st March, 2025 |
|---|---|---|
| As per Balance Sheet | 590.77 | 130.39 |
| Balance as per statement of cash flows | 590.77 | 130.39 |
Annexure A:
| Sr No | Particulars | Details |
|---|---|---|
| 1 | Name of the Company | Sandu Pharmaceuticals Limited |
| 2 | CIN | L24233GA1985PLC001587 |
| 3 | Outstanding borrowing of the Company as on 31st March 2026 | 0 |
| 4 | Highest Credit rating during the previous FY along with the name of Credit rating Agency | NA |
| 5 | Name of the Stock Exchange on which fine to be levied in case of shortfall in the required borrowing under the framework | NA |